Company Overview and News

 
Multi Finance to top up capital with Rs200mn private placement

2018-07-20 lankabusinessonline
July 20, 2018 (LBO) – Central Bank of Sri Lanka (CBSL) registered finance company Multi Finance is to increase its capital base by way of private placement.
MFL

 
Multi Finance PLC enables sustainable transactions with “Each One Plant One” campaign

2018-03-21 lankabusinessonline
With a proud heritage of over 4 decades in business, Multi Finance PLC has been a source of strength to businesses, and entrepreneurs in the urban rural and SME markets, playing a pivotal role in contributing to the growth of the Sri Lankan economy.
MFL

 
CB Governor makes clarion call for political stability

2018-03-21 dailymirror.lk
Sri Lanka cannot afford to deviate from the path it has embarked upon and ensuring political stability is of paramount importance to attain sustained economic growth for the country, according to Central Bank Governor Dr.Indrajit Coomraswamy.
MFL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CSE:MFL / MULTI FINANCE PLC on message board site Silicon Investor.

Minefinders, MFL Minefinders, MFL Minefinders, MFL Microfluidics- MFLU. Microfluidics- MFLU. Microfluidics- MFLU.
MFLM - MAGELLAN FILMED ENTERTAINMENT MFLM - MAGELLAN FILMED ENTERTAINMENT MFLM - MAGELLAN FILMED ENTERTAINMENT MFLE... Hollywood excitement for 1 cent MFLE... Hollywood excitement for 1 cent MFLE... Hollywood excitement for 1 cent
Moldflow Corporation (MFLO) - Plastic CAE Market Leader Moldflow Corporation (MFLO) - Plastic CAE Market Leader Moldflow Corporation (MFLO) - Plastic CAE Market Leader CAMFLO RESOURCES LTD CFK (ASE) ACQUIRES INTERNET COMPANY CAMFLO RESOURCES LTD CFK (ASE) ACQUIRES INTERNET COMPANY CAMFLO RESOURCES LTD CFK (ASE) ACQUIRES INTERNET COMPANY
Minefinders (V.MFL) Minefinders (V.MFL) Minefinders (V.MFL)